Kidney Cancer | Tumor

Age May Not Impact Outcomes from Metastatic Renal Cell Carcinoma Treatment Despite Increased Toxicity in Older Patients

January 11th 2021, 2:00pm


Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.

Phase 2 Study of Novel Drug and Cabometyx Combo in Advanced or Metastatic Kidney Cancer Fails to Meet its Main Goal of Improving Progression-Free Survival

January 5th 2021, 10:00pm


Patients with advanced or metastatic kidney cancer treated with the novel drug combination achieved a median progression-free survival of 9.2 months compared to 9.3 months among patients who received Cabometyx with a placebo.

Kidney Cancer News and Updates That Patients May Have Missed in 2020

January 5th 2021, 4:00pm


A roundup of some kidney cancer news and updates that occurred in 2020 that patients may have missed.

Deciding Whether to Receive the COVID-19 Vaccine — and Which One — As More Are Authorized for Emergency Use by the FDA

December 21st 2020, 7:00pm


With the second COVID-19 vaccine receiving emergency use authorization by the FDA, patients with cancer undergoing treatment should keep in mind how it may affect their therapy and the potential difference between the two vaccines by Pfizer-BioNTech and Moderna.

Promising Drug Puts Focus on Rare Condition That Can Lead to Growth of Tumors, Cysts

November 5th 2020, 7:00pm


The FDA is reviewing what could become the first-ever medication specifically for kidney cancer associated with von Hippel-Lindau disease.

Can a Blood Test Detect Cancer in Asymptomatic Patients?

October 28th 2020, 3:00pm


A liquid biopsy may soon be available to find early signs of cancer in asymptomatic patients when the disease is still treatable and even curable.

FDA Grants Priority Review to Opdivo-Cabometyx Combo for Advanced Kidney Cancer

October 27th 2020, 6:00pm


The FDA granted a priority review to the biologics license application and new drug application for the combination of Opdivo and Cabometyx for patients with advanced kidney cancer.

Cabometyx-Tecentriq Combo Shows Promise in Advanced Kidney Cancer

October 5th 2020, 3:00pm


“The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” Dr. Sumanta Kumar Pal, co-director of the Kidney Cancer Program at City of Hope in California, said during a presentation of the clear cell renal cell carcinoma cohort.

Surgery After Targeted or Immune Therapy Improves Health Outcomes in Some Patients with Metastatic Kidney Cancer

October 1st 2020, 1:00pm


For some patients with metastatic kidney cancer, undergoing surgery after targeted or immune therapy sparks better health outcomes.

Data Sharing, Vigilance Pivotal in Maintaining Patient Safety While Treating Cancer Amid the COVID-19 Pandemic

September 2nd 2020, 3:00pm


As the COVID-19 pandemic continues to impact the care of patients with metastatic renal cell carcinoma and other cancers, health care professionals are working together to stay vigilant and make the best treatment decisions for their patients by pooling their data with tools like the COVID-19 and Cancer Consortium, says Dr. Toni K. Choueiri.